Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Acrivon Therapeutics, Inc. (ACRV)

Acrivon Reports Q1 2026 Net Loss of $19.0 Million, Down From $19.7 Million

Positive Impact 3 of 5 earnings Written later

Acrivon Therapeutics reported a first-quarter 2026 net loss of $19.0 million, or $0.49 per share, compared with $19.7 million, or $0.51 per share, a year earlier. Lower general and administrative expenses offset flat research and development spending, and the company said its cash is expected to fund operations into the third quarter of 2027.

Key points

  • Net loss for the quarter ended March 31, 2026 was $19.0 million, versus $19.7 million a year earlier; net loss per share was $0.49, versus $0.51.
  • General and administrative expenses fell to $4.7 million from $6.2 million, mainly due to lower employee-related expenses including stock-based compensation.
  • Research and development expenses were $15.2 million, versus $15.4 million a year earlier.
  • Cash, cash equivalents and marketable securities were $97.7 million at March 31, 2026, plus $7.3 million in proceeds from subsequent equity financing.

The filing

CompanyAcrivon Therapeutics, Inc. (ACRV)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:10 PM ET
Accession number0001193125-26-221626

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.